TNFA TNF Pharmaceuticals Inc.: Enterprise Value to EBITDA Ratio
TNF Pharmaceuticals (TNFA) relies on a virtual business model, outsourcing compound synthesis and clinical trials to external partners. The company develops advanced methods to combat cellular senescence to increase healthy longevity. This EV/EBITDA valuation chart is fixed at , while the business updates its development portfolio by repurposing legacy anti-inflammatory drugs for geriatric needs.
Comprehensive metric breakdowns and analytics for tnfpharma.com (TNFA)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity TNF Pharmaceuticals|TNFA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio TNF Pharmaceuticals, Inc.|TNFA - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio TNF Pharmaceuticals, Inc.|TNFA - Company Long-Term Indebtedness|Company Short-Term Debts TNF Pharmaceuticals|Quick Liquidity Indicator tnfpharma.com
- financial results and valuation multiples details:
TNFA - Final Profit|Expected Profit TNF Pharmaceuticals|TNFA - Market Cap to Net Income|Forward P/E Multiple TNF Pharmaceuticals, Inc.|TNFA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple TNF Pharmaceuticals, Inc.|TNFA - Operating profit EBITDA|Earnings per share for the last twelve months TNF Pharmaceuticals|TNFA - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months tnfpharma.com|TNFA - Net earnings per share growth this year|Earnings growth forecast for next year TNF Pharmaceuticals
General company analysis:TNFA (TNF Pharma)
The market values the capitalization of TNF Pharmaceuticals (TNFA) through the lens of its development efficiency in targeted therapy. The company's EV/EBITDA ratio on this chart compares the total enterprise value, including debt, with operating profit before interest, taxes, depreciation, and amortization, determining the asset payback period. The decline of this indicator amid the implementation of innovative treatments for autoimmune diseases confirms the issuer's fundamental undervaluation and financial stability.
Competitor analysis for TNF Pharmaceuticals
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|ANI Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio MNKD (MannKind Corp)|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PCRX (Pacira Corp) - Enterprise Value to Operating Income Before Depreciation|SPRY: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio TBPH (theravance.com)|Enterprise Value to EBITDA Ratio AQST|SCPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|TNXP: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple SXTC (China SXT Pharmaceuticals, Inc.)|Business Value to Operating Income Before Depreciation EPRX|BioHarvest Sciences Inc. - EV/EBITDA Multiple|EXOZ - EV/EBITDA Multiple|oramed.com (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Entera Bio - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MindWalk Holdings|Enterprise Value to EBITDA Ratio abvcpharma.com (ABVC)|EV/EBITDA Multiple CPIX|EV/EBITDA Multiple Quantum BioPharma Ltd. (QNTM)|EV/EBITDA Multiple FGEN (FibroGen Corp)|TELO - Enterprise Value to EBITDA Ratio|Rani Therapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA Synergy CHC Corp|RLYB (rallybio.com) - Enterprise Value to EBITDA Ratio|Lexaria Bioscience Corp. (LEXX) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PULM|PTHL (Pheton) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple APM|Total Company Value to Operating Income Before Depreciation Ratio lyratherapeutics.com|EV/EBITDA Multiple IBO (Impact BioMedical)|YCBD - Enterprise Value to EBITDA Ratio|PainReform Limited - EV/EBITDA Multiple|CYTO - EV/EBITDA Multiple|Lipella Pharmaceuticals (LIPO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OPTN (optinose.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals, Inc.|Procaps Group (PROC) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio PTPI (Petros)|Enterprise Value to Operating Income Before Depreciation Ratio QLI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|TFFP: Enterprise Value to Operating Income Before Depreciation
